BeOne Medicines Ltd. — Director's Dealing 2019

Jun 7, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2019-06-05

Reporting Person: Wu Xiaobin (President & GM China)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-05	Ordinary Shares	A	433472	—	Acquired	1505956	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-05	Share Option (Right to Buy)	$9.23	A	797550	Acquired	2029-06-04	Ordinary Shares (797550.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
American Depositary Shares	4000	Indirect

Footnotes

F1: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F2: Each American Depositary Share represents 13 Ordinary Shares.

F3: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

F4: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.